Across TCGA pan-cancer cohorts, VAMP8 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated VAMP8 data layer compared with 28 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher VAMP8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated VAMP8 expression acts as an unfavorable survival marker.
CESC and SARC are the cancer types where VAMP8 Mutation most reproducibly stratifies survival.